Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

References

• Gotay CC, Kawamoto T, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26:1355–63.
   PubMed Web of Science ®Google Scholar
• Sehlen S, Marten-Mittag B, Herschbach P, Schweden M, Book K, Henrich G, et al.Health-related quality of life supersedes other psychosocial predictors of long-term survival in cancer patients undergoing radiotherapy. Acta Oncol 2012;51:1020–8.
   PubMed Web of Science ®Google Scholar
• Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009;7:102–23.
   PubMed Web of Science ®Google Scholar
• Cassileth BR, Lusk EJ, Miller DS, Brown LL, Miller C. Psychosocial correlates of survival in advanced malignant disease?N Engl J Med 1985;312:1551–5.
   PubMed Web of Science ®Google Scholar
• Cassileth BR, Walsh WP, Lusk EJ. Psychosocial correlates of cancer survival: A subsequent report 3 to 8 years after cancer diagnosis. J Clin Oncol 1988;6:1753–9.
   PubMed Web of Science ®Google Scholar
• Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, et al.Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993; 29:1731–4.
   Web of Science ®Google Scholar
• Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, et al.Quality of life evaluation in a randomized trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer 2003;39:1577–85.
   PubMed Web of Science ®Google Scholar
• Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, et al.Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009;10: 865–71.
   PubMed Web of Science ®Google Scholar
• Efficace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, et al.Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicentre study. J Clin Oncol 2004;22;3381–8.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KI, Trudeau ME, Koo J, et al.Health-related quality of life and psychosocial status in breast cancer prognosis: Analysis of multiple variables. J Clin Oncol 2004;22:4184–92.
   PubMed Web of Science ®Google Scholar
• Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002;20:3106–13.
   PubMed Web of Science ®Google Scholar
• Brown JE, Butow PN, Culjak G, Coates AS, Dunn SM. Psychosocial predictors of outcome: Time to relapse and survival in patients with early stage melanoma. Br J Cancer 2000;83:1448–53.
   PubMed Web of Science ®Google Scholar
• Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychosocial distress and fatigue predicted recurrence and survival in primary breast cancer patients. Br J Cancer 2007;105:209–19.
   Google Scholar
• Efficace F, Therasse P, Piccart MJ, Coens C, Van Steen K, Welnicka-Jaskiewicz M, et al.Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicentre study. J Clin Oncol 2004;22:3381–8.
   PubMed Web of Science ®Google Scholar
• Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, et al.Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): A randomized phase 3 trial. Lancet Oncol 2011;12:144–52.
   PubMed Web of Science ®Google Scholar
• Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, et al.Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer 2012;48:2012–9.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al.The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Aronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring Manual, 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001.
   Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–6.
   PubMedGoogle Scholar
• Sauerbrei W, Schumacher A. A boostrap resampling procedure for model building: Application to the Cox regression model. Stat Med 1992;11:2093–109.
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139–44.
   PubMed Web of Science ®Google Scholar
• Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 1999;17: 2256–63.
   PubMed Web of Science ®Google Scholar
• Canada AL, Fawzy NW, Fawzy FI. Personality and disease outcome in malignant melanoma. J Psychosom Res 2005; 58:19–27.
   PubMed Web of Science ®Google Scholar
• Lehto US, Ojanen M, Dyba T, Aromaa A, Kellokumpu-Lehtinen P. Baseline psychosocial predictors of survival in localized melanoma. J Psychosom Res 2007;63:9–15.
   PubMed Web of Science ®Google Scholar
• Bergenmar M, Nilsson B, Hansson J, Brandberg Y. Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale as predictors of time to recurrence in localized cutaneous melanoma. Acta Oncol 2004;43:161–8.
   PubMed Web of Science ®Google Scholar
• Brandberg Y, Mansson-Brahme E, Ringborg U, Sjödén PO. Psychological reactions in patients with malignant melanoma. Eur J Cancer 1995;31A:157–62.
   PubMed Web of Science ®Google Scholar